Tg Therapeutics Inc.

Address: 3020 Carrington Mill Boulevard Suite 475

Sponsor Overview

assignment

Specializations

Multiple Sclerosis and Relapsing Disease Forms

Tg Therapeutics Inc. focuses on relapsing multiple sclerosis and related relapsing disease presentations, with clinical activity centered on long-term safety, efficacy, and radiological outcomes in people living with active disease.

Relapsing forms of multiple sclerosis
Relapsing multiple sclerosis
Radiological disease activity

The sponsor’s work in this area includes adult and pediatric populations, reflecting interest across different stages of multiple sclerosis care.

Anti-CD20 Immunotherapy

Clinical research also addresses anti-CD20 therapy in autoimmune disease, with attention to treatment response in participants who have had a suboptimal experience with prior therapy and to maintaining disease control over time.

Anti-CD20 therapy
Autoimmune diseases
Treatment response

This therapeutic area links immune modulation with neurologic disease management, especially in relapsing conditions.

Pediatric Neurology

The sponsor funds studies in children and adolescents with relapsing forms of multiple sclerosis, highlighting interest in age-specific treatment performance, safety, and clinical effectiveness in younger patients.

Pediatric multiple sclerosis
Adolescent patients
Long-term safety

These studies extend the sponsor’s neurologic research into earlier disease onset and pediatric treatment needs.

Pharmacokinetics and Pharmacodynamics

A substantial part of the sponsor’s portfolio examines pharmacokinetics and pharmacodynamics of ublituximab, including comparisons of intravenous and subcutaneous administration and evaluation of relative bioavailability.

Ublituximab
Intravenous and subcutaneous administration
Relative bioavailability

Research in this domain includes both delivery route exploration and device-based administration approaches.

Biologic Delivery and Administration Devices

Tg Therapeutics Inc. is also involved in studies of subcutaneous injection methods, including different injection sites and use of an autoinjector device versus syringe, with a focus on treatment practicality in multiple sclerosis.

Subcutaneous injection
Autoinjector device
Injection site evaluation

These areas reflect interest in how biologic therapies are administered in routine neurologic care.

Trial Name	Country	Status
Efficacy Assessment of Ublituximab in Combination with Cetirizine, Dexamethasone, Paracetamol, Methylprednisolone, and Diphenhydramine in Relapsing Multiple Sclerosis	Poland	Recruiting
Evaluation of Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous vs. Intravenous Ublituximab in Relapsing Multiple Sclerosis	Bulgaria Croatia Czechia Hungary	Not Recruiting
Open-Label Extension Study Evaluating Long-Term Safety and Efficacy of Ublituximab in Patients with Relapsing Multiple Sclerosis	Croatia Poland	Not Recruiting
Pharmacokinetic and Pharmacodynamic Assessment of Ublituximab in Myasthenia Gravis and Relapsing Multiple Sclerosis with Methylprednisolone Combination	Poland	Not Recruiting
Phase 2 Study of the Pharmacokinetics, Safety, and Relative Bioavailability of Subcutaneous Ublituximab via Autoinjector versus Syringe in Patients with Multiple Sclerosis	Poland	Recruiting
Ublituximab in Pediatric Participants with Relapsing forms of Multiple Sclerosis (RMS)	Poland Slovakia	Recruiting